Working to Eradicate Gynecologic Cancers

Andres Poveda, MD

Department of Medical Oncology
Fundación Instituto Valenciano de Oncología
Fundación Instituto Valenciano de Oncología
Valencia Spain 46009

Papers:
4 - Seminal Abstract A phase III, randomized, double-blind trialof weekly paclitaxel plus the angiopoientin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1 99 - Featured Poster Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: exploratory analysis of phase III OVA-301 study